Skip to main content

Mammoplasty

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Xequel Bio
Xequel BioSC - Mount Pleasant
1 program
1
Granexin® gel 100 μMPhase 2/3
Biocorp
BiocorpFrance - Issoire
1 program
1
Granexin® gel 100 μMPhase 2/31 trial
Active Trials
NCT04331080Completed184Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpGranexin® gel 100 μM

Clinical Trials (1)

Total enrollment: 184 patients across 1 trials

NCT04331080BiocorpGranexin® gel 100 μM

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

Start: Jul 2020Est. completion: May 2022184 patients
Phase 2/3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.